SuperworthNurix Therapeutics shares outstanding NRIX
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Aug 31, 2026
- 116.2M
- On a year earlier
- +38.0%
- more shares
Nurix Therapeutics had 116.2M diluted shares outstanding on average in Q3 FY26, the quarter to Aug 31, 2026.
That is 38.0% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 95.1M | +21% |
| FY2024 | 78.4M | +43% |
| FY2023 | 54.7M | +1% |
| FY2022 | 53.9M | +21% |
| FY2021 | 44.6M | +15% |
| FY2020 | 38.7M | +1250% |
| FY2019 | 2.9M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q3 FY26 | 116.2M | +38% | |
| Q2 FY26 | 111.1M | +32% | |
| Q1 FY26 | 110.1M | +32% | |
| Q4 FY25 | 95.1M | +21% | |
| Q3 FY25 | 84.2M | +16% | |
| Q2 FY25 | 83.9M | +34% | |
| Q1 FY25 | 83.6M | +52% | |
| Q4 FY24 | 78.4M | +43% | |
| Q3 FY24 | 72.8M | +34% | |
| Q2 FY24 | 62.4M | +15% | |
| Q1 FY24 | 54.9M | +2% | |
| Q4 FY23 | 54.7M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Nurix Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.